Searched for
CIPLA AND LUPIN
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- India Inc's foreign investments more than double in AprilIndian companies significantly boosted overseas investments in April. Direct investments surged to $3.37 billion, more than doubling from M...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Nithya Balasubramanian on 2 pharma names to bet on besides Sun & Cipla“Coming to the complex generics opportunity, Cipla and Lupin are most exposed. We like Cipla more than Lupin because at least in the near t...
- Cipla, Lupin may gain from Perrigo's drug recall, says MacquariePerrigo announced the voluntary nationwide recall of albuterol sulfate following complaints that some units may not dispense due to cloggin...
- Licence to sell cancer drug biggest opportunity for Dr Reddy’s in US market: Nirmal Bang‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’
- Pharma is seeing flight to safety, market yet to price in multi-year EPS growth: Sanford Bernstein'There is definitely room beyond the re-rating that the market has already seen, which should come from more and more of these complex gene...
- Lupin, Cipla numbers raise hopes of a recoveryWe are pleased with the robust all-round performance in our key markets, said Lupin MD.
- US show a plus for Cipla, Lupin confident of recoveryThe domestic business grew 6 per cent, showing the impact of a high base effect.
- HDFC Securities’ Amey Chalke on future of pharma cos“There are mixed signals on pricing pressure for pharma cos in US.”
- YES Bank, IndusInd Bank to join BSE Sensex; shares upOn the other hand, drug makers - Cipla and Lupin - will be dropped from the index.
- HSBC says US generic probe concern to weigh on sentiment for pharma cosShares of Sun Pharmaceutical will be closely watched due to its material exposure to doxycycline development amid report that doxycycline-a...
- Experts re-rate pharma stocks post weak Q1 showAfter the first-quarter earnings, the once bullish analysts are re-rating stocks of Dr Reddy’s, Lupin and Cipla. We tell you why.
- Who moved my market on ThursdayIn this space, ETMarkets.com tracks the elite 30 from the Sensex pack and 50 from the nimble Nifty LIVE to help you understand why the mark...
- Cipla, Ranbaxy to outperform pharma space: KR Choksey SecOne will have to look at Cipla and Ranbaxy as the potential candidate for outperformance in the pharma space in coming year.
- Buy Lupin on Rs 10-15 downside: Ashwani GujralLupin is tending to find support often around these 415-420 zones, so it is broadly range bound.
- Japan's Takeda eyes Lupin, Cipla pharma business; shares surge in morning tradeShares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Cipla, Lupin shares surge in morning trade on boursesShares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Japan's Takeda eyes Lupin, Cipla pharma businessTakeda, Japan's largest pharmaceutical firm, has begun talks with two of India's biggest companies for purchasing either of their pharma bu...
Load More
